shutterstock_274590824

Sanofi accuses MSD of US patent infringement

pharmafile | September 19, 2016 | News story | Sales and Marketing MSD, Sanofi, lawsuit 

Sanofi has filed a suit against MSD in the United States District Court for the District of Delaware accusing the US firm of infringing ten of its patents.

This move comes after a notification that MSD has filed a New Drug Application with the FDA for an insulin glargine drug product; the company asserts that its NDA included a paragraph IV certification challenging all of the ten patents listed in the FDA Orange Book for Sanofi’s Lantus and Lantus SoloStar products.

Matt Fellows

Related Content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib …

Sanofi shares phase 2b results for dermatitis treatment

Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study …

Sanofi to acquire Inhibrx for approximately $1.7bn

Sanofi and Inhibrx, Inc have announced that they have entered into a definitive agreement for …

Latest content